Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-21
2000-08-22
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514261, 544254, A01N 4354
Patent
active
061073008
ABSTRACT:
Corticotropin releasing factor (CRF) antagonists of formula I or formula II: ##STR1## and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
REFERENCES:
patent: 4076711 (1978-02-01), Ganguly et al.
patent: 5639752 (1997-06-01), Macor
J. Rivier et al., Proc. Natl. Acad. Sci., 80:4851 (1983).
W. Vale et al., Science, 213:1394 (1981).
W. Vale et al., Rec. Prog. Horm. Res., 39:245 (1983).
G.F. Koob, Persp. Behav. Med., 2:39 (1985).
E.B. De Souza et al., J. Neurosci., 5:3189 (1985).
J.E. Blalock, Physiological Reviews, 69:1 (1989).
J.E. Morley, Life Sci., 41:527 (1987).
E.B. DeSouza, Hosp. Practice, 23:59 (1988).
C.B. Nemeroff et al., Science, 226:1342 (1984).
C.M. Banki et al., Am. J. Psychiatry, 144:873 (1987).
R.D. France et al., Biol. Psychiatry, 23:86 (1988).
M. Arato et al., Biol. Psychiatry, 25:355 (1989).
C.B. Nemeroff et al., Arch. Gen. Psychiatry, 45:577 (1988).
P.W. Gold et al., Am. J. Psychiatry, 141:619 (1984).
F. Holsboer et al., Psychoneuroendocrinology, 9:147 (1984).
P.W. Gold et al., New Eng. J. Med., 314:1129 (1986).
R.M. Sapolsky, Arch. Gen. Psychiatry, 46:1047 (1989).
Grigoriadis et al., Neuropsychopharmacology, 2:53 (1989).
D.R. Britton et al., Life Sci., 31:363 (1982).
C.W. Berridge & A.J. Dunn, Regul. Peptides, 16:83 (1986).
C.W. Berridge & A.J. Dunn, Horm. Behav., 21:393 (1987).
Brain Research Reviews, 15:71 (1990).
K.T. Britton et al., Psychopharmacology, 86:170 (1985).
N.R. Swerdlow et al., Psychopharmacology, 88:147 (1986).
K.T. Britton et al., Psychopharmacology, 94:306 (1988).
G.F. Koob & K.T. Britton, Corticotropin-Releasing Factor: Basic & Clinical Studies of a Neuropeptide, E.B. DeSouza & C.B. Nemeroff, CRC Press, p. 221 (1990).
Remington's Pharmaceutical Sciences, 17.sup.th ed., Mack Pub. Co., Easton, PA, p. 1418 (1985).
Albert, Brown & Wood, J. Chem. Soc., 3832 (1954).
Munson & Rodbard, Anal. Biochem., 107:220 (1980).
G. Battaglia et al, Synapse, 1:572 (1987).
Tanji et al., Chem. Pharm. Bull., 39(11), 3037-3040 (1991).
Settimo et al., Il Farmaco, Ed. Sc., 35(4), 308-323 (1980).
Biagi et al., Il Farmaco, 49(3), 183-186 (1994).
Thompson et al., J. Med. Chem., 34, 2877-2882 (1991).
Kelley et al., J. Med. Chem., 31, 606-612 (1990).
Kelley et al., J. Med. Chem., 33, 1360-1363 (1990).
Kelley et al., J. Heterocyclic Chem., 28, 1099 (1991).
Khairy et al., J. Heterocyclic Chem., 22, 853 (1985).
Arvanitis Argyrios Georgios
Bakthavatchalam Rajagopal
Beck James Peter
Cain Gary Avonn
Chorvat Robert John
Dupont Pharmaceuticals
Kerr Don M.
Patel Sudhaker B.
Raymond Richard L.
LandOfFree
Arylamino fused pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylamino fused pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylamino fused pyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-581377